BioCentury
ARTICLE | Clinical News

Cenderitide: Phase II started

March 9, 2015 7:00 AM UTC

Capricor began an open-label, dose-escalation, U.S. Phase II trial to evaluate 0.5, 1, 2 and 3 ng/kg/min cenderitide given as a 48-hour continuous infusion via the Insulet Drug Delivery System for up ...